Trial Profile
A Pilot Study of IV [intravenous] Clofarabine for Patients With Myelodysplastic Syndrome Who Have Failed 5-Azacytidine.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 24 Aug 2013
Price :
$35
*
At a glance
- Drugs Clofarabine (Primary)
- Indications Myelodysplastic syndromes
- Focus Adverse reactions; Therapeutic Use
- 01 Jun 2012 Actual end date (Mar 2010) added as reported by ClinicalTrials.gov.
- 26 Mar 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 05 Feb 2010 Planned end date changed from 1 Mar 2011 to 1 Mar 2012 as reported by ClinicalTrials.gov.